N
N. Costedoat-Chalumeau
Researcher at Sorbonne
Publications - 26
Citations - 313
N. Costedoat-Chalumeau is an academic researcher from Sorbonne. The author has contributed to research in topics: Antiphospholipid syndrome & Pregnancy. The author has an hindex of 9, co-authored 26 publications receiving 223 citations. Previous affiliations of N. Costedoat-Chalumeau include Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study
Amelia Ruffatti,Marta Tonello,Ariela Hoxha,Savino Sciascia,Maria José Cuadrado,José Omar Latino,Sebastián Udry,Tatiana Reshetnyak,N. Costedoat-Chalumeau,N. Costedoat-Chalumeau,Nathalie Morel,Luca Marozio,Angela Tincani,Laura Andreoli,Ewa Haladyj,Pier L. Meroni,Maria Gerosa,Jaume Alijotas-Reig,Sara Tenti,Karoline Mayer-Pickel,Michal J. Simchen,Maria Tiziana Bertero,Sara De Carolis,Véronique Ramoni,Arsène Mekinian,Elvira Grandone,Aldo Maina,Fátima Serrano,Vittorio Pengo,Munther A. Khamashta,Munther A. Khamashta,Munther A. Khamashta +31 more
TL;DR: In this paper, the effect of additional treatments combined with conventional therapy on pregnancy outcomes was examined in high-risk primary antiphospholipid syndrome (PAPS) patients to identify the most effective treatment strategy.
Journal ArticleDOI
mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G.
Jérôme Hadjadj,Jérôme Hadjadj,Guillaume Canaud,Guillaume Canaud,Tristan Mirault,Maxime Samson,Patrick Bruneval,Alexis Régent,Claire Goulvestre,Véronique Witko-Sarsat,Véronique Witko-Sarsat,N. Costedoat-Chalumeau,N. Costedoat-Chalumeau,Loïc Guillevin,Luc Mouthon,Benjamin Terrier +15 more
TL;DR: Results suggest that antibodies targeting ECs drive endothelial remodelling in TA through activation of the mTOR pathway, but not in GCA, and could represent a therapeutic option in TA.
Journal ArticleDOI
Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study
Adrien Mirouse,Raphaèle Seror,Eric Vicaut,Xavier Mariette,Maxime Dougados,Anne-Laure Fauchais,Alban Deroux,Azeddine Dellal,N. Costedoat-Chalumeau,Guillaume Denis,Jérémie Sellam,Jean-Benoît Arlet,Christian Lavigne,Geoffrey Urbanski,Dominique Fischer-Dumont,Abdou Diallo,Olivier Fain,Arsène Mekinian +17 more
TL;DR: In this article, the authors describe the characteristics and the outcome of primary Sjogren Syndrome (pSS) associated arthritis and compare the efficacy of different therapeutic regimen using Club Rhumatisme and Inflammation and French Internal Medicine Society (SNFMI) networks.
Journal ArticleDOI
Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies.
Micaela Fredi,Laura Andreoli,Elena Aggogeri,Elisa Bettiga,Maria Grazia Lazzaroni,Véronique Le Guern,Andrea Lojacono,Nathalie Morel,J.C. Piette,Sonia Zatti,N. Costedoat-Chalumeau,N. Costedoat-Chalumeau,Angela Tincani +12 more
TL;DR: Maternal and fetal complications were observed in some aPL-positive patients despite their efficient management according to the current recommendations and a higher risk of APO was observed in patients with a previous thrombosis and/or more complex autoimmune phenotype.
Journal ArticleDOI
Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients.
Arsène Mekinian,Guillaume Dervin,Nathanael Lapidus,Jean-Emmanuel Kahn,Louis Terriou,Eric Liozon,Eric Grignano,Jean-Charles Piette,Odile Beyne Rauzy,Vincent Grobost,Pascal Godmer,Jerome Gillard,Julien Rossignol,David Launay,Achille Aouba,Thierry Cardon,Laurence Bouillet,Jonathan Broner,Julien Vinit,Lionel Ades,Fabrice Carrat,Clémentine Salvado,Eric Toussirot,Mathilde Versini,N. Costedoat-Chalumeau,N. Costedoat-Chalumeau,Jean Baptiste Fraison,Jean Baptiste Fraison,Philippe Guilpain,Pierre Fenaux,Olivier Fain +30 more
TL;DR: This nationwide study demonstrates the efficacy of steroids for SIAD-associated MDSs but a high frequency of steroid dependence, and the response to biologics seems low, but rituximab and azacytidine seem promising.